At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABBV AbbVie
Market Closed 10-23 16:00:00 EDT
285.64
+0.45
+0.16%
盘后285.01
-0.63-0.22%
19:56 EDT
High286.77Low282.30Vol4.63M
Open284.58D1 Closing285.19Amplitude1.57%
Mkt Cap504.84BTradable Cap503.57BTotal Shares1.77B
T/O1.32BT/O Rate0.26%Tradable Shares1.76B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

A 42% Risk Reduction—and an 18% Stock Drop
Bellwether Stocks Movement  ·  10-24 22:29
A 42% Risk Reduction—and an 18% Stock Drop
Moderna’s Cancer Vaccine Passed Phase 3. What Spooked Investors?
Bellwether Stocks Movement  ·  10-24 12:44
Moderna’s Cancer Vaccine Passed Phase 3. What Spooked Investors?
Earning Preview: AbbVie Q3 revenue is expected to increase by 11.29%, and institutional views are predominantly bullish
Earnings Agent  ·  10-24 00:05
Earning Preview: AbbVie Q3 revenue is expected to increase by 11.29%, and institutional views are predominantly bullish
AbbVie Files Initial Beneficial Ownership Statement for Director John Carethers
Reuters  ·  10-24 05:05
AbbVie Files Initial Beneficial Ownership Statement for Director John Carethers
FDA Approves Subcutaneous Induction for AbbVie's Skyrizi in Crohn's Disease
Reuters  ·  10-24 03:34
FDA Approves Subcutaneous Induction for AbbVie's Skyrizi in Crohn's Disease
Abbvie: FDA Approves Update to Skyrizi U.S. Prescribing Information Allowing Clinical Judgment on Tuberculosis Testing Across All Indications
THOMSON REUTERS  ·  10-24 03:33
Abbvie: FDA Approves Update to Skyrizi U.S. Prescribing Information Allowing Clinical Judgment on Tuberculosis Testing Across All Indications
U.S. FDA Approves Subcutaneous Induction Regimen for Abbvie's Skyrizi® (Risankizumab-Rzaa) for Adults with Moderately to Severely Active Crohn's Disease
THOMSON REUTERS  ·  10-24 03:33
U.S. FDA Approves Subcutaneous Induction Regimen for Abbvie's Skyrizi® (Risankizumab-Rzaa) for Adults with Moderately to Severely Active Crohn's Disease
AbbVie Price Target Raised to $294.00/Share from $258.00 by Goldman Sachs
Dow Jones  ·  10-24 02:11
AbbVie Price Target Raised to $294.00/Share from $258.00 by Goldman Sachs
UK Approves J&J's Oral Psoriasis Pill
Reuters  ·  10-23 20:09
UK Approves J&J's Oral Psoriasis Pill
Avalo Therapeutics downgraded to Neutral at Guggenheim after AbbVie data
TIPRANKS  ·  10-23 19:36
Avalo Therapeutics downgraded to Neutral at Guggenheim after AbbVie data
Avalo Therapeutics Abdakibart Potential Intact After AbbVie Data, Wedbush Says
MT Newswires Live  ·  10-23 00:45
Avalo Therapeutics Abdakibart Potential Intact After AbbVie Data, Wedbush Says
AbbVie Targets Essential Tremor With New Mid-Stage Trial, Adding Depth to Its Neurology Pipeline
TIPRANKS  ·  10-23 00:31
AbbVie Targets Essential Tremor With New Mid-Stage Trial, Adding Depth to Its Neurology Pipeline
MoonLake Jumps as AbbVie's Weak Skin Drug Data Eases Competition Fears
Reuters  ·  10-23 00:17
MoonLake Jumps as AbbVie's Weak Skin Drug Data Eases Competition Fears
Avalo Plunges After Rival AbbVie's Skin Drug Trial Disappoints
Reuters  ·  10-22 23:36
Avalo Plunges After Rival AbbVie's Skin Drug Trial Disappoints
Avalo Therapeutics Shares Down 37% After Rival Abbvie Reports Skin Drug Trial Data
THOMSON REUTERS  ·  10-22 23:33
Avalo Therapeutics Shares Down 37% After Rival Abbvie Reports Skin Drug Trial Data
AbbVie's Skin Disease Drug Reduces Lesions in Trial, Company Eyes Weight-Loss Combination
Reuters  ·  10-22 23:06
AbbVie's Skin Disease Drug Reduces Lesions in Trial, Company Eyes Weight-Loss Combination
Movement Alert｜AbbVie Falls 3.25% in Pre-Market Trading, Pullback Comes Despite Fresh Analyst Price-Target Increases Ahead of Earnings
Market Focus  ·  10-22 21:17
Movement Alert｜AbbVie Falls 3.25% in Pre-Market Trading, Pullback Comes Despite Fresh Analyst Price-Target Increases Ahead of Earnings
AbbVie’s Lutikizumab Meets Primary Endpoint in Phase 3 Hidradenitis Suppurativa Trial
Reuters  ·  10-22 21:04
AbbVie’s Lutikizumab Meets Primary Endpoint in Phase 3 Hidradenitis Suppurativa Trial
Abbvie Announces Topline Results from the Phase 3 Intrepid Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
THOMSON REUTERS  ·  10-22 21:00
Abbvie Announces Topline Results from the Phase 3 Intrepid Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
Abbvie: Lutikizumab Met 8 Ranked Secondary Endpoints in Trial
THOMSON REUTERS  ·  10-22 21:00
Abbvie: Lutikizumab Met 8 Ranked Secondary Endpoints in Trial

Introduction

Company Name.
AbbVie
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Issue price:
--